Open Orphan PLC is a publicly traded company listed on the London Stock Exchange (LSE) under the ticker symbol ORPH. The company is listed on the Euronext Growth Market in Dublin under the same ticker symbol. As of this post, Open Orphan Share Price is at 17.30 GBX.
Open Orphan PLC is a European-focused, rapidly growing pharmaceutical services company that provides testing and development services to pharmaceutical and biotechnology companies. The company was formed in June 2019 following the merger of Venn Life Sciences and Open Orphan Limited.
Open Orphan has a range of services, including clinical trial management, data management and analysis, regulatory support, and consultancy. The company focuses on the growing area of human challenge trials, which involve deliberately infecting healthy volunteers with viruses to test the efficacy of potential vaccines and treatments.
In 2020, Open Orphan acquired hVIVO, a world leader providing viral challenge study services. This acquisition significantly expanded Open Orphan’s capabilities and gave the company access to a state-of-the-art quarantine facility in London.
Open Orphan has offices in Ireland, the UK, France, the Netherlands, and the US. The company has experienced significant growth in recent years and is well-positioned to capitalise on the increasing demand for clinical trial services, particularly in infectious diseases.
The demand for clinical trial services is expected to grow significantly in the coming years due to the increasing focus on developing treatments and vaccines for infectious diseases. Open Orphan is well-positioned to capitalise on this trend, mainly focusing on the growing area of human challenge trials.
Open Orphan Share Price has a highly experienced management team with a track record of success in the pharmaceutical and biotech industries. The team deeply understands the clinical trial process and is well-positioned to execute the company’s growth strategy.
Open Orphan Share Price has a range of services, including clinical trial management, data management and analysis, regulatory support, and consultancy. This diversification of revenue streams can help to mitigate risks associated with a reliance on a single product or service.
Open Orphan’s acquisition of hVIVO in 2020 significantly expanded its capabilities and gave it access to a state-of-the-art quarantine facility in London. In addition, the company’s management team has indicated that it will continue seeking strategic acquisitions to drive growth.
- IQVIA. IQVIA is a global provider of clinical trial services, including data management, biostatistics, and regulatory support.
- PPD. PPD is a contract research organisation that provides clinical trial management services, including patient recruitment and study monitoring.
- Parexel. Parexel is a global biopharmaceutical services company that provides services to support developing and commercialising new treatments.
- Charles River Laboratories. Charles River Laboratories is a contract research organisation that provides preclinical and clinical laboratory services to pharmaceutical and biotech companies.
- Covance. Covance is a global contract research organisation that supports drug development, including clinical trial management, central laboratory services, and drug safety monitoring.
It’s important to note that the competitive landscape in the pharmaceutical services industry can be highly dynamic, and new entrants and mergers and acquisitions can change the competitive environment rapidly.
